Lixte Biotechnology (NASDAQ:LIXT) Stock Price Up 0.5% – Here’s Why

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT)’s share price shot up 0.5% on Friday . The company traded as high as $4.14 and last traded at $4.07. 38,006 shares changed hands during trading, a decline of 53% from the average session volume of 81,454 shares. The stock had previously closed at $4.05.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Lixte Biotechnology in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Lixte Biotechnology has a consensus rating of “Sell”.

Lixte Biotechnology Price Performance

The company has a market cap of $30.44 million, a price-to-earnings ratio of -3.45 and a beta of 0.88. The firm has a fifty day simple moving average of $4.23 and a 200 day simple moving average of $3.92.

Lixte Biotechnology (NASDAQ:LIXT) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.33) earnings per share (EPS) for the quarter.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.